Deep dive on SGLT2 inhibitors with a focus on Jardiance® (empagliflozin)
Promotional material from the Boehringer Ingelheim and Lilly Diabetes Alliance
This eLearning module has been commissioned and funded by the Boehringer Ingelheim and Lilly Diabetes Alliance and developed in partnership with Guidelines in Practice and Guidelines Learning. Products are discussed.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for: